Sun, Jan 25, 2015, 2:08 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Hittite Microwave Corporation (HITT) Message Board

sudnwealth 40 posts  |  Last Activity: Jan 11, 2015 2:27 AM Member since: Nov 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Coming wave of new Cancer drugs
    The hottest area in cancer drugs is going mainstream this year.

    If 2014 proved that the most promising new group of oncology drugs in generations could work, 2015 brings a crowded field that sees winners and losers in a market eventually worth $30 billion a year or more in the next decade.

    The treatments, known broadly as immunotherapies or immune-oncology, fall into two major categories -- drugs that help take the brakes off the immune response, going after solid tumors like melanoma and lung cancer, and customized treatments that modify immune cells to combat blood malignancies.

    “I think 2015 is the end of the beginning in the story of immunotherapy,” said Michael Giordano, head of development of oncology and immunology at Bristol-Myers Squibb Co. “2015 will be a pivot point where I-O will be mainstreamed beyond melanoma and we’ll start seeing it approved and used in large tumors.”

    There are 374 experimental cancer drugs in mid-stage trials, according to the IMS Institute for Healthcare Informatics’ global outlook report published last year. That’s more than twice as many drugs as for nervous system disorders, for example. Of the experimental cancer drugs, about 25 percent to 30 percent are immunotherapies, according to IMS.

    In trials, Merck & Co. and Bristol-Myers’ drugs showed long-lasting effects in some patients that oncologists have called dramatic.

    There a huge unmet medical need from patients, for whom many new treatments extend lives by years, rather than months. And the financial reward for drugmakers is huge. The drugs have annual costs of $150,000, and a slate of personalized treatments are expected to carry even higher price tags.

    Surging Stocks

    Kite Pharma Inc., Juno Therapeutics Inc. and Bluebird Bio Inc. have gathered interest from investors for their therapies to modify the immune system cells and retrain them to attack blood cancers, a technique known as CAR. Kite and Bluebird rose more than fourfold in the last year, while Juno’s shares have more than doubled since their initial public offering last month. All three companies are scheduled to present at the JPMorgan Health Care Conference in San Francisco next week.

    Kite plans to file for regulatory approval for its treatment by end of 2016, according to spokesman Justin Jackson. Juno plans to file an application by late 2016 or early 2017, according to company filings.

    Bristol-Myers and Merck, meanwhile, are racing to expand their drugs beyond melanoma. They expect approvals in lung cancer this year, and are testing on a wide range of solid tumors.

    Combination Treatments

    They’re also pushing related immune-oncology drugs through their pipelines that will used in combination with one another. While their drugs have only shrunk tumors in about 30 percent of the population, combinations may help broaden their use.

    They’ll have competition. In 2015, AstraZeneca Plc, Roche AG and Merck may all release data on new immune system mechanisms, according to Seamus Fernandez, an analyst with Leerink Partners. In combination treatments, AstraZeneca “has now advanced from ‘dark horse’ to ‘major contender,’’ Fernandez said. ‘‘Real leadership remains wide open.’’

    Roche has more than 20 molecules in its immunotherapy pipeline, and looks to leverage the broad portfolio to craft combination therapies, Daniel O’Day, chief operating officer of the drugmaker’s pharmaceuticals division, said in an October conference call.

    Boutique Treatments

    Large drugmakers are also joining forces with biotechnology companies for their boutique blood cancer treatments. While questions linger about the cost and scalability of the CAR therapies, bigger biotechs and pharma companies are jumping into the fray nonetheless.

    There have already been four licensing deals adding up to more than $1 billion, including an agreement between Amgen Inc. and Kite valued at as much $525 per therapy, plus royalties.

    Celgene Corp. has a pact for as much as $225 million per product with Bluebird Bio, and Pfizer Inc. has promised Paris-based Cellectis $80 million upfront and milestone payments of as much as $185 million to share in their CAR program. Novartis AG is also working on the therapy.

    ‘‘A new pillar of cancer care is now firmly established,” Fernandez wrote in a Dec. 29 note to clients. As treatments begin to hit the market and new drug combinations and cancer types are explored, “things are just getting interesting,” he said. Less
    Sort: Newest | Oldest | Most Replied Collapse all replies
    hdwrsft • 2 minutes 58 seconds ago
    0users liked this postsusers disliked this posts0Reply
    ......lets pass 'em all!!!!!!!!! Lol!
    Back To Board

  • chinaman.nyc2003 • Jan 3, 2015 6:35 AM Flag

    users liked this posts

    users disliked this posts

    Down to 65
    Be sure to take a screenshot of it

  • chinaman-you have told me before I have good insight and knowledge. Here is my insight and knowledge: you are both a pumper and a shorter depending on the day and company. This can be seen by your incessant pumping here, followed by your negative comments after taking your profits as well as your negative comments at NWBO. Yes, the other company you are currently investing in, ADXS, has a lot of potential. But that means nothing to CTIX. So please take your useless, incendiary, and stupid comments and leave. 1) There is no reason whatsoever to believe there is a trial delay. 2) I don't care if there is one. All that the management has done here is manage to make an investment on our behalf (B) that once the trial is complete will be shown to worth many billions as per the recent Merck merger. If he wanted to delay 6 months, my 30,000 shares would vote yes because I want it done right and frankly all of his decisions have benefited my long term interests thus far.

    Please take your bipolar stupidity and leave. Less

  • First bio ever to do it! Best part, besides retiring, for me. Watching china moron get nuked all the way

  • Reply to

    Next Week

    by ervm Jan 4, 2015 12:15 PM
    sudnwealth sudnwealth Jan 5, 2015 12:59 AM Flag

    What do you think their worth if someone does buy them...mmmm

  • Reply to

    Good drug terribly high valuation

    by chinaman.nyc2003 Jan 2, 2015 9:00 AM
    sudnwealth sudnwealth Jan 4, 2015 12:59 PM Flag

    Run along now chinaman, go back to pumping the living #$%$ out of ADXS on the ADXS dont mind negative posts here as long as they have substance...

  • Reply to

    I will be a buyer

    by sudnwealth Jan 2, 2015 12:18 AM
    sudnwealth sudnwealth Jan 3, 2015 3:39 PM Flag

    forarmy -- ur an idiot and will be crushed by being short this name. I know ur not smart but if you u were u would cover now before your losses become catastrophic

  • Reply to

    I will be a buyer

    by sudnwealth Jan 2, 2015 12:18 AM
    sudnwealth sudnwealth Jan 2, 2015 3:44 PM Flag

    In for 4000 shares now or about 50% of what I planned to invest. Will buy 4K more next over the next 2-3 weeks. I like our chances. BTW very long BLUE since $35--check my posts.

  • sudnwealth by sudnwealth Jan 2, 2015 12:18 AM Flag

    Been doing my DD. Like what I see and will scale in.

  • Reply to

    First Post

    by oncodoc78 Dec 18, 2014 12:27 AM
    sudnwealth sudnwealth Dec 28, 2014 10:46 PM Flag

    Welcome! Its good to have some docs on board..

  • again! Celgene is smart and they partnered with a leader.

  • Reply to

    Here is what the lawsuit is all about

    by dcxavier Dec 26, 2014 9:52 AM
    sudnwealth sudnwealth Dec 27, 2014 5:42 PM Flag

    I would submit that once he became privy to the results in December, it would have been illegal to sell. Besides he wanted to surprise the Mrs. with a new Lexus, lol. This lawsuit wont go anywhere and he left a ton of money on the table. Good grief, the ambulance chasers must have had a tough year.

  • sudnwealth sudnwealth Dec 25, 2014 4:19 PM Flag

    I don't think they would sell this for under $200 a share....possibly $250

  • Reply to


    by slumdawg2011 Dec 23, 2014 11:44 AM
    sudnwealth sudnwealth Dec 24, 2014 1:07 AM Flag

    IMGN has so much more going for it ... lol ... see ya at $200 on BLUE

  • QIDP and Cubist buyout were game changers Recommend not listening to the fudsters...looking forward to $5's and 6's soon..much to like with this little bio

  • Reply to

    Used the dip to add

    by sudnwealth Sep 29, 2014 10:40 AM
    sudnwealth sudnwealth Dec 15, 2014 11:17 PM Flag

    R U kidding me? I'm up several hundred thousand dollars in BLUE. Gapped from 49 to $83 in one day. No intention of selling and yep 2.65 million shares @$85 bucks after they can rewrite biotech history

  • I like holding extraordinary bios with mucho cash...these guys will change the face of biotech imo

  • Reply to

    $85 is a great price!

    by faosto Dec 15, 2014 9:31 PM
    sudnwealth sudnwealth Dec 15, 2014 9:32 PM Flag

    I agree Faosto! market will like this going forward

  • Next week FDA gives the green light to run P3 and within 2-3 weeks they announce a very favorable partnership with a BP company, we uplist to Nasdaq in Q1-2015, and trade at $8-9 short term...double digits 2nd half of 2015. This opinion doesn't account for upside surprises in K or Prurisol which may in fact prove my forecasts to be on the low side. All IMO of course, but I intend to hold for at least another year and watch the story develop...and am not discounting one bit an outright purchase of CTIX for $15-20 per share.

    Sentiment: Strong Buy

  • Reply to

    Used the dip to add

    by sudnwealth Sep 29, 2014 10:40 AM
    sudnwealth sudnwealth Dec 13, 2014 10:09 PM Flag

    I still watch SGEN and should the sentiment change will return. Wish good things for the company and shareholders
    Ps; BLUE will rewrite medical history though imo. Has the potential to go to $1,000

78.000.00(0.00%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.